The European Patent Office’s (EPO) Board of Appeal revoked Novo Nordisk’s patent EP 3 448 416, which covered its semaglutide products Wegovy and Ozempic. The pa

The European Patent Office’s (EPO) Board of Appeal revoked Novo Nordisk’s patent EP 3 448 416, which covered its semaglutide products Wegovy and Ozempic. The patent could have protected the products until 2037. Following the ruling, market exclusivity could end as early as 2031. The decision may al…